A patch preparation which can produce the effect for preventing any problems due to the misuse of the patch preparation, includes a support and a plaster wherein the plaster includes a) an aliphatic compound with hydrophilic group which is in solid state at room temperature, b) a non-aqueous adhesive, and c) a solvent with a vapor pressure of 1 kPa or more at 20° C.

A patch for at least partially reducing at least one of pain, swelling, inflammation and irritation in at least one body part of a user is provided. The patch includes at least one cloth layer having the propolis composition embedded therein. The patch includes a first plastic layer disposed immediately against a first side of the at least one cloth layer, and a second plastic layer disposed immediately against a second side of the at least one cloth layer opposite the first side, such that the at least one cloth layer is sandwiched between the first and second plastic layers. The propolis composition is configured to at least partially reduce at least one of perceived pain, swelling, inflammation and irritation when the patch is applied to the at least one body part. Related methods of use and/or manufacture for such a patch are also provided.

The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

The present invention provides a patch for relieving lumbago, the patch comprising a backing and an adhesive layer laminated on the backing, wherein the adhesive layer comprises an adhesive base and 0.70 to 1.50 mg of diclofenac sodium per cm.sup.2 of application area, and the patch is used by applying the patch once a day to the chest region, the abdominal region, the dorsal region, the brachial region, or the femoral region of a human.

Disclosed is a patch for relieving cancer pain, the patch comprising a support layer, and an adhesive layer laminated on the support layer, wherein the adhesive layer contains an adhesive base and diclofenac sodium. The patch is applied once a day, and is used such that the dosage of the diclofenac sodium is 150-225 mg per dose.

To provide a packaging body for a patch exhibiting excellent temporal stability of a drug, a patch product equipped with the patch and a packaging bag, and a method of manufacturing the patch product.

A patch product equipped with a packaging bag formed of a laminate composed of at least three or more layers including a cyclic polyolefin film and a lidocaine- or rivastigmine-containing patch housed in the packaging bag, a method of the patch product, and a packaging body for a patch formed of a laminate including a cyclic polyolefin film.

A method for the treatment of a local pigmentation disorder comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient.

Disclosed is a patch containing a plaster having fentanyl, an adhesive, a volatile hydrocarbon solvent (A), and a heteroatom-containing volatile organic solvent (B).

A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.